A Meta Analysis For Survival Effection Of Postoperative Invasive Bladder Cancer Patients Treated By Neoadjuvant Chemotherapy

Objective:To explore the curative effect of neoadjuvant chemotherapy combined bladder resection for invasive bladder cancer.Methods:Data were retrieved from the Medline, Embase, the Cochrane database, etc. Time interval from January 2000 to December 2014, randomized controlled experimental study undergone with neoadjuvant chemotherapy combined bladder resection for invasive bladder cancer were included. All literature were selected according to inclusion and exclusion criteria, a total of 14 studies were selected, they were divided into two different groups, with neoadjuvant chemotherapy plus surgery or radiotherapy as the experimental group, surgery or radiotherapy alone as the control group, a total of 3306 cases were included, including neoadjuvant chemotherapy treatment group 1633 cases, randomized control group 1673 cases accordingly. The different treatment options and 5-year survival rate were evaluated using meta analysis method.Results:Compared with control group, the neoadjuvant chemotherapy group with a 19% lower risk ratio of death odds, OR 0.81 (95% CI:0.72-0.92). Subgroup analysis had also shown (OR 0.81,95% CI 0.67 to 0.99), there is no difference in the platinum chemotherapy alone group, it could not reduce the risk of death significantly, but cisplatin combined with chemotherapy regimens, such as GC scheme and MVAC scheme, can reduce the risk of death in patients, and improve the overall survival of patients significantly.Concision:Neoadjuvant chemotherapy combined bladder resection for invasive bladder cancer may significantly reduce the patient’s death risk, improve the overall survival ratio.In particular, combined chemotherapy with cisplatin-based, can obviously improve the prognosis, and improve the quality of life of patients after surgery.